Neuro3d identifies candidate compound

Neuro3d, a biopharmaceutical company focused on drug discovery and development, announced today that Johnson & Johnson Pharmaceutical Research & Development (J&JPRD) in Beerse, Belgium, has identified a compound for further characterization from Neuro3d's propriety libraries and has extended the research collaboration with Neuro3d.

"The identification of this compound and extension of the research collaboration by J&JPRD further highlights the strength of Neuro3d's internal drug discovery capabilities. As this achievement is outside the psychiatric arena which is our main area of focus, we are now demonstrating the ability to leverage our expertise into other indications," noted Charles Woler, CEO of Neuro3d. "We look forward to the continued success of our collaboration with J&JPRD."

Neuro3d SA is a French pharmaceutical company focused on discovery and development of innovative treatments for psychiatric disorders such as schizophrenia, depression or anxiety.